Study Data from David Geffen School of Medicine University of California Los Angeles (UCLA) Update Understanding of Pancreatic Cancer (Promoter Methylation Leads to Hepatocyte Nuclear Factor 4A Loss and Pancreatic Cancer Aggressiveness).

A study conducted by researchers at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA) has identified a potential target for the treatment of pancreatic cancer. The study found that the silencing of a gene called Hepatocyte Nuclear Factor 4A (HNF4A) through promoter DNA methylation contributes to the development and aggressiveness of pancreatic cancer, leading to poor patient survival. The researchers used a combination of in vitro and in vivo studies, as well as gene and protein expression analyses in pancreatic cancer patients, to support their findings. This research provides valuable insights into the epigenetic regulation of pancreatic cancer and may contribute to the development of new therapeutic strategies. [Extracted from the article]

Copyright of Cancer Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)